Metagenomi to Present at Jefferies Global Healthcare Conference in London

Core Insights - Metagenomi, Inc. is an in vivo genome editing company focused on developing curative genetic medicines using proprietary technologies [3][4] - The company will present at the Jefferies Global Healthcare Conference in London on November 20, 2025 [1] - Metagenomi's lead program, MGX-001, targets hemophilia A and has shown a competitive preclinical profile compared to existing treatments [4] Company Overview - Metagenomi specializes in metagenomics, utilizing genetic materials from the environment to create novel genome editing tools [3] - The company aims to correct various genetic mutations and is focused on high-value disease indications with clear clinical pathways [3] Product Development - MGX-001 is designed to provide lifelong protection from bleeding events in hemophilia A patients through a one-time treatment [4] - The company is also exploring treatments for secreted protein deficiencies and cardiometabolic diseases using its genome integration system [4]